tbuckley/cabot-search huggingface dataset:
Abstract P3-03-31: Is sentinel lymph node biopsy necessary in all patients with early breast cancer?
Authors: KH Yoon, KB Lee, H Lee, J Lee, JY Kim, HS Park, S Park, SI Kim, YU Cho, B-W Park
Journal: Cancer Research (2019)

Abstract Background and objectives : Since the results of the American College of Surgeons Oncology Group Z0011 published, the criteria for applying axillary lymph node (ALN) dissection was relaxed among early breast cancer patients who were scheduled for breast conserving surgery, adjuvant chemotherapy therapy, and adjuvant radiation therapy. SLNB criteria may be established if pathologic nodal status can be predicted. The aim of this study was to develop a nomogram for preoperative prediction of axillary node metastasis. Methods: The records of 1650 patients with T1, T2 primary invasive breast cancer who were treated between January 2013 and September 2016 were selected from the medical database of Yonsei University (Seoul, South Korea). Those whom a preoperative diagnosis of axillary node metastases were excluded. Two nomogram that predicted three or more axillary metastasis and one or more axillary metastasis were developed using a binary logistic regression model with a training cohort. Internal validation was carried out adopting bootstrap method by validation cohort 500 times resampling. Result: A total of 82 (4.8%) patients had three or more ALNs metastasis. Three hundred seventy five (17.4%) patients had one or more ALNs metastasis. Axillary metastasis was associated with Preoperative ALN suspicious image findings, clinical tumor size, Number of neoplastic foci, estrogen receptor status, Ki-67 expression, tumor marker. The nomogram was developed based on the clinical and statistically significant predictors. It had good discrimination performance (AUC 0.79, 95% CI, 0.73–0.85), (AUC 0.71, 95% CI, 0.67–0.74) and calibration fit. Conclusion:Our nomogram might help predict the ALN metastasis in breast cancer patients. Patients with a low probability of ALN metastasis could be spared SLNB. Citation Format: Yoon KH, Lee KB, Lee H, Lee J, Kim JY, Park HS, Park S, Kim SI, Cho YU, Park B-W. Is sentinel lymph node biopsy necessary in all patients with early breast cancer? [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-31.
Transparent Disclosure of Conflicts of Interest
Authors: Deepak Agrawal, Waqas Haque
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P6-17-20: Withdrawn
Authors: TT Junttila, D Ellerman, N Lombana, M Hristopoulos, R Clark, J Li, R Vij, JT Koerber, J Johnston, A Shelton, E Mai, K Gadkar, AA Lo, K Totpal, R Prell, G Lee, C Spiess, D Slaga
Journal: Cancer Research (2019)

Abstract This abstract was withdrawn by the authors. Citation Format: Junttila TT, Ellerman D, Lombana N, Hristopoulos M, Clark R, Li J, Vij R, Koerber JT, Johnston J, Shelton A, Mai E, Gadkar K, Lo AA, Totpal K, Prell R, Lee G, Spiess C, Slaga D. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-20.
Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis
Authors: Saul Soberanes, Alexander V. Misharin, Amit Jairaman, Luisa Morales-Nebreda, Alexandra C. McQuattie-Pimentel, Takugo Cho, Robert B. Hamanaka, Angelo Y. Meliton, Paul A. Reyfman, James M. Walter, Ching-I Chen, Monica Chi, Stephen Chiu, Francisco J. Gonzalez-Gonzalez, Matthew Antalek, Hiam Abdala-Valencia, Sergio E. Chiarella, Kaitlyn A. Sun, Parker S. Woods, Andrew J. Ghio, Manu Jain, Harris Perlman, Karen M. Ridge, Richard I. Morimoto, Jacob I. Sznajder, William E. Balch, Sangeeta M. Bhorade, Ankit Bharat, Murali Prakriya, Navdeep S. Chandel, Gökhan M. Mutlu, G.R. Scott Budinger
Journal: Cell Metabolism (2019)
Abstract P4-15-04: Neoadjuvant endocrine therapy for ER+ DCIS can lead to disease regression and allows BCS in up to a third of patients with disease &amp;gt;40mm at diagnosis
Authors: CW Cartlidge, N Johns, RJ Hackney, AK Turnbull, JM Dixon
Journal: Cancer Research (2019)

Abstract Background: The role of neoadjuvant endocrine therapy (NET) for ER+ DCIS is an area of evolving study. It may allow down-sizing prior to surgery, converting DCIS requiring mastectomy to disease suitable for breast conservation surgery (BCS). Here we report the results from the first European single-institution series of its type. Methods: Data were prospectively collected from patients diagnosed with ER+ DCIS and treated with NET prior to surgery, at a single unit between 2009 -2015. The size of the tumour on initial imaging (mammography) was compared to the size of the tumour on final imaging and pathology using RECIST criteria to determine disease progression. Blocks from initial core biopsy and final pathology are being interrogated by immunohistochemistry and DNA and RNA comparisons. Results: 42 patients diagnosed with ER+ DCIS received NET with median age at diagnosis of 63y (range 37-94y). 7/42 premenopausal women were treated with tamoxifen, 35/42 post-menopausal women were treated with letrozole. 36/42 (85.7%) patients underwent surgery with 18/36 (50%) requiring mastectomy and 18/36 (50%) treated by BCS. 3/18 (16.7%) of the BCS patients required re-excision for positive margins. The median time to operation was 72d (range 15-308d). In total 12/42 (28.6%) had invasive disease on final pathology. 2/36 (5.6%) patients had a pathological complete response (PCR), 14/36 (38.9%) had a partial response (PR), 17/36 (47.2%) had stable disease and 3/36 (8.3%) had larger disease on pathology than imaging; this is a common feature of many lower grade DCIS lesions. 26/42 (61.9%) patients initially had DCIS &amp;gt;40mm (largest 240mm) and yet 9/26 (34.6%) of these patients still underwent successful BCS. There was a significant correlation between length of endocrine therapy and reduction in size of disease. Immunohistochemical and molecular analyses are ongoing. Conclusions: •NET is an effective treatment for ER+ DCIS. It reduces the rate of re-excision to 16.7% in this series - substantially lower than the national (UK) figures for DCIS at 30%. •It produces path CRs (5.6%) and high response rates that relate to the duration of treatment. •This unique study shows that the optimal duration of NET is of the order of 6 months, achieving high rates of conversion for mastectomy to BCS. Citation Format: Cartlidge CW, Johns N, Hackney RJ, Turnbull AK, Dixon JM. Neoadjuvant endocrine therapy for ER+ DCIS can lead to disease regression and allows BCS in up to a third of patients with disease &amp;gt;40mm at diagnosis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-15-04.
Abstract SY33-04: Role of shelterin in cancer and aging: Generation of conditional knockout mice for TRF1, TPP1, and RAP1
Authors: Maria Blasco
Journal: Cancer Research (2010)

Abstract Shelterin is a highly conserved chromosome end-capping complex, which encompasses TRF1, TRF2, TPP1, POT1, TIN2 and RAP1. Although extensive cell culture studies suggest that shelterin is essential for telomere regulation, its role in telomere biology and disease in the context of the organism remained elusive due to lack of viable loss-of-function mouse models. I will report on mice and cells conditionally deleted for TRF1, TPP1 and RAP1. While deletion of TRF1 and TPP1 in mouse stratified epithelia results in perinatal mortality, severe skin atrophy and hyperpigmentation, and widespread epithelial dysplasia and tumors in the absence of p53, RAP1 deletion does not affect mouse viability and only leads to mild skin hyperpigmentation at aduldhood. This differential impact of TPP1 and TRF1 deletion compared to RAP1 deletion is in agreement with severe telomere uncapping produced by either TPP1 or TRF1 abrogation, which is not observed upon RAP1 deletion. These results argue that RAP1 is not an essential telomere capping protein in mammals. Instead, we show here that both TPP1 and RAP1 are important to recruit telomerase to telomeres and to maintain telomere length. In addition, we demonstrate that RAP1 is important for silencing of genes located near the telomeres, demonstrating a conserved role of RAP1 in subtelomeric gene silencing from yeast to mammals. Citation Format: Maria Blasco. Role of shelterin in cancer and aging: Generation of conditional knockout mice for TRF1, TPP1, and RAP1 [abstract]. In: Proceedings of the AACR 101st Annual Meeting 2010; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr SY33-04
Hydroa vacciniforme–like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites
Authors: Jeffrey I. Cohen, Irini Manoli, Kennichi Dowdell, Tammy A. Krogmann, Deborah Tamura, Pierce Radecki, Wei Bu, Siu-Ping Turk, Kelly Liepshutz, Ronald L. Hornung, Hiva Fassihi, Robert P. Sarkany, Lori L. Bonnycastle, Peter S. Chines, Amy J. Swift, Timothy G. Myers, Melissa A. Levoska, John J. DiGiovanna, Francis S. Collins, Kenneth H. Kraemer, Stefania Pittaluga, Elaine S. Jaffe
Journal: Blood (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Authors: Brian I Rini, Thomas Powles, Michael B Atkins, Bernard Escudier, David F McDermott, Cristina Suarez, Sergio Bracarda, Walter M Stadler, Frede Donskov, Jae Lyun Lee, Robert Hawkins, Alain Ravaud, Boris Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault-Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C Green, Robert J Motzer
Journal: The Lancet (2019)
Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases
Authors: Ioana Agache, Isabella Annesi‐Maesano, Andreas Bonertz, Francesco Branca, Andrew Cant, Zlatko Fras, Frank Ingenrieth, Leyla Namazova‐Baranova, Mikaela Odemyr, Antonio Spanevello, Stefan Vieths, Arzu Yorgancioglu, Montserat Alvaro‐Lozano, Domingo Barber Hernandez, Tomás Chivato, Stefano Del Giacco, Zuzana Diamant, Ibon Eguiluz‐Gracia, Roy Gert van Wijk, Philippe Gevaert, Anke Graessel, Peter Hellings, Karin Hoffmann‐Sommergruber, Marek Jutel, Susanne Lau, Antti Lauerma, Jose Maria Olaguibel, Liam O'Mahony, Cevdet Ozdemir, Oscar Palomares, Oliver Pfaar, Joaquin Sastre, Glennis Scadding, Carsten Schmidt‐Weber, Peter Schmid‐Grendelmeier, Mohamed Shamji, Isabel Skypala, Monica Spinola, Otto Spranger, Maria Torres, Andrea Vereda, Sergio Bonini
Journal: Allergy (2019)

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients' organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
Abstract P5-18-07: Withdrawn
Authors: F Yang, S Wu, M Mo, Y Liu, G Liu
Journal: Cancer Research (2019)

Abstract This abstract was withdrawn by the authors. Citation Format: Yang F, Wu S, Mo M, Liu Y, Liu G. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-18-07.
Putting a price on alcohol
Authors: Katherine Bettany
Journal: BMJ (2014)

Medical students are renowned for their love of cheap alcohol, and rates of alcohol abuse in the medical professionals are well documented. Students and doctors aren’t alone in this—Britain, like many countries in Europe, faces a public health crisis over the widespread overconsumption of alcohol. An issue that the UK government has flip-flopped over is the introduction of minimum unit pricing to try and drive up the cost of alcohol. In their feature on p 16 , Alice Buchan and Sally Marlow look at the evidence behind …
Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation
Authors: Nicole Freise, Alina Burghard, Theresa Ortkras, Niklas Daber, Achmet Imam Chasan, Saskia-L. Jauch, Olesja Fehler, Julia Hillebrand, Mosab Schakaki, Jessica Rojas, Bodo Grimbacher, Thomas Vogl, Andreas Hoffmeier, Sven Martens, Johannes Roth, Judith Austermann
Journal: Blood (2019)
Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial
Authors: Jasvinder A. Singh, Liana Fraenkel, Candace Green, Graciela S. Alarcón, Jennifer L. Barton, Kenneth G. Saag, Leslie M. Hanrahan, Sandra C. Raymond, Robert P. Kimberly, Amye L. Leong, Elyse Reyes, Richard L. Street, Maria E. Suarez-Almazor, Guy S. Eakin, Laura Marrow, Charity J. Morgan, Brennda Caro, Jeffrey A. Sloan, Bochra Jandali, Salvador R. Garcia, Jennifer Grossman, Kevin L. Winthrop, Laura Trupin, Maria Dall’Era, Alexa Meara, Tara Rizvi, W. Winn Chatham, Jinoos Yazdany
Journal: PLoS Medicine (2019)

Background Treatment decision-making regarding immunosuppressive therapy is challenging for individuals with lupus. We assessed the effectiveness of a decision aid for immunosuppressive therapy in lupus nephritis. Methods and findings In a United States multicenter, open-label, randomized controlled trial (RCT), adult women with lupus nephritis, mostly from racial/ethnic minority backgrounds with low socioeconomic status (SES), seen in in- or outpatient settings, were randomized to an individualized, culturally tailored, computerized decision aid versus American College of Rheumatology (ACR) lupus pamphlet (1:1 ratio), using computer-generated randomization. We hypothesized that the co-primary outcomes of decisional conflict and informed choice regarding immunosuppressive medications would improve more in the decision aid group. Of 301 randomized women, 298 were analyzed; 47% were African-American, 26% Hispanic, and 15% white. Mean age (standard deviation [SD]) was 37 (12) years, 57% had annual income of <$40,000, and 36% had a high school education or less. Compared with the provision of the ACR lupus pamphlet (n = 147), participants randomized to the decision aid (n = 151) had (1) a clinically meaningful and statistically significant reduction in decisional conflict, 21.8 (standard error [SE], 2.5) versus 12.7 (SE, 2.0; p = 0.005) and (2) no difference in informed choice in the main analysis, 41% versus 31% (p = 0.08), but clinically meaningful and statistically significant difference in sensitivity analysis (net values for immunosuppressives positive [in favor] versus negative [against]), 50% versus 35% (p = 0.006). Unresolved decisional conflict was lower in the decision aid versus pamphlet groups, 22% versus 44% (p < 0.001). Significantly more patients in the decision aid versus pamphlet group rated information to be excellent for understanding lupus nephritis (49% versus 33%), risk factors (43% versus 27%), medication options (50% versus 33%; p ≤ 0.003 for all); and the ease of use of materials was higher in the decision aid versus pamphlet groups (51% versus 38%; p = 0.006). Key study limitations were the exclusion of men, short follow-up, and the lack of clinical outcomes, including medication adherence. Conclusions An individualized decision aid was more effective than usual care in reducing decisional conflict for choice of immunosuppressive medications in women with lupus nephritis. Trial registration Clinicaltrials.gov, NCT02319525.
Abstract B24: Delineating the roles of lysine 27 methylation-associated epigenetic modulators in T cell leukemia.
Authors: Panagiotis Ntziachristos, Grant Welstead, Thomas Trimarchi, Sofia Bakogianni, Luyao Xu, Pieter Van Vlierberghe, Rab Prinjha, Adolfo Ferrando, Rudolf Jaenisch, Charles Mullighan, Aifantis Iannis
Journal: Clinical Cancer Research (2015)

Abstract This abstract is being presented as a short talk. A full abstract is printed in the Proffered Abstracts section (PR03) of the Conference Proceedings. Citation Format: Panagiotis Ntziachristos, Grant Welstead, Thomas Trimarchi, Sofia Bakogianni, Luyao Xu, Pieter Van Vlierberghe, Rab Prinjha, Adolfo Ferrando, Rudolf Jaenisch, Charles Mullighan, Aifantis Iannis. Delineating the roles of lysine 27 methylation-associated epigenetic modulators in T cell leukemia. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr B24.
Resource-rationality beyond individual minds: the case of interactive language use
Authors: Mark Dingemanse
Journal: Behavioral and Brain Sciences (2020)

Abstract Resource-rational approaches offer much promise for understanding human cognition, especially if they can reach beyond the confines of individual minds. Language allows people to transcend individual resource limitations by augmenting computation and enabling distributed cognition. Interactive language use, an environment where social rational agents routinely deal with resource constraints together, offers a natural laboratory to test resource-rationality in the wild.
Abstract P4-14-10: Withdrawn
Authors: M Ekholm, P-O Bendahl, M Fernö, B Nordenskjöld, O Stål, L Rydén
Journal: Cancer Research (2019)

Abstract This abstract was withdrawn by the authors. Citation Format: Ekholm M, Bendahl P-O, Fernö M, Nordenskjöld B, Stål O, Rydén L. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-14-10.
Abstract P2-01-22: KLF4 improve prognosis of triple negative breast cancer by suppression of epitherial mesenchymal transition
Authors: T Nagata, S Sekine, M Arai, T Fujii
Journal: Cancer Research (2019)

Abstract Background Triple negative breast cancer (TNBC) is highly malignant and prone to metastasis and relapse, and therefore has poorer prognosis than other sub-types. The mechanism of higher malignancy of TNBC has not been sufficiently elucidated. KLF4is reported to be a transcription factor that is associated with both tumor suppression and oncogenesis. We have reported that breast cancer patients with strong expression of KLF4 had better prognosis, especially in TNBC patients. And here we report that KLF4 negatively regulates the metastasis and growth of TNBC. Methods We assessed the expression levels of KLF4 in 84 patients with TNBC by immunohistochemical staining and studied the patterns of metastasis/recurrence clinicopathologically. The overall survival (OS) rate and the disease free survival (DFS) rate after surgery was calculated by Kaplan-Maier method. In addition, circulating tumor cells (CTCs) in the peripheral blood of TNBC patients were identified and compared with primary lesions in terms of KLF4 expression. Moreover, the expression of KLF4 was inhibited by transfecting cultured TNBC cells (MDA-MB231) with the small interfering RNA (siRNA) of KLF4 to analyze the effects of KLF4 on cell proliferation and epithelial-mesenchymal transition (EMT)-like changes. For the proliferation assay, measurements were made by MTT assays. Cell migration and invasion assays of KLF4 suppressed TNBC cells were also examined. Total RNA was extracted from these cells, cDNA was synthesized, and used for the quantitative polymerase chain reaction (qPCR) analysis. Results In the 84 TNBC patients, higher KLF4 expression was associated with significantly better OS and DFS. An analysis of KLF4 expression in CTCs of the TNBC patients showed that KLF4 expression was lower in CTCs than in primary cancer lesions. TNBC cells (MDA-MB231) that were transfected the KLF4 siRNA exhibited a greater ability to growth than controls. These cells also underwent EMT-like changes with reduced expression of epithelial factors such as E-cadherin. Treating these TNBC cells with eribulin resulted a reduction of the expression of stem cell/EMT markers. Conclusion TNBC patients with reduced KLF4 expression had poor outcomes. The results of our experiments suggest the expression of KLF4 is one of the important factors that inhibit the EMT and growth of TNBC. Citation Format: Nagata T, Sekine S, Arai M, Fujii T. KLF4 improve prognosis of triple negative breast cancer by suppression of epitherial mesenchymal transition [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-01-22.